Intravenous Administration of Bone Marrow-Derived Mesenchymal Stem Cells Induces a Switch from Classical to Atypical Symptoms in Experimental Autoimmune Encephalomyelitis
Potent immunosuppressive and regenerative properties of mesenchymal stem cells (MSCs) position them as a novel therapy for autoimmune diseases. This research examines the therapeutic effect of MSCs administration at different disease stages in experimental autoimmune encephalomyelitis (EAE). Classic...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.1155/2015/140170 |
id |
doaj-fe5da1fb37a24073bcfaaec3d0839bad |
---|---|
record_format |
Article |
spelling |
doaj-fe5da1fb37a24073bcfaaec3d0839bad2020-11-24T22:53:47ZengHindawi LimitedStem Cells International1687-966X1687-96782015-01-01201510.1155/2015/140170140170Intravenous Administration of Bone Marrow-Derived Mesenchymal Stem Cells Induces a Switch from Classical to Atypical Symptoms in Experimental Autoimmune EncephalomyelitisMónica Kurte0Javiera Bravo-Alegría1Alexander Torres2Vania Carrasco3Cristina Ibáñez4Ana María Vega-Letter5Catalina Fernández-O’Ryan6Carlos E. Irarrázabal7Fernando E. Figueroa8Rodrigo A. Fuentealba9Claudia Riedel10Flavio Carrión11Laboratory of Cellular and Molecular Immunology, Faculty of Medicine, University of Los Andes, 750000 Santiago, ChileLaboratory of Cellular and Molecular Immunology, Faculty of Medicine, University of Los Andes, 750000 Santiago, ChileLaboratory of Cellular and Molecular Immunology, Faculty of Medicine, University of Los Andes, 750000 Santiago, ChileLaboratory of Cellular and Molecular Immunology, Faculty of Medicine, University of Los Andes, 750000 Santiago, ChileLaboratory of Cellular and Molecular Immunology, Faculty of Medicine, University of Los Andes, 750000 Santiago, ChileLaboratory of Cellular and Molecular Immunology, Faculty of Medicine, University of Los Andes, 750000 Santiago, ChileLaboratory of Cellular and Molecular Immunology, Faculty of Medicine, University of Los Andes, 750000 Santiago, ChileLaboratory of Integrative and Molecular Physiology, Faculty of Medicine, University of Los Andes, 750000 Santiago, ChileLaboratory of Cellular and Molecular Immunology, Faculty of Medicine, University of Los Andes, 750000 Santiago, ChileLaboratory of Cellular and Molecular Immunology, Faculty of Medicine, University of Los Andes, 750000 Santiago, ChileDepartment of Biological Sciences, Faculty of Biological Sciences, Andrés Bello National University, 8370146 Santiago, ChileLaboratory of Cellular and Molecular Immunology, Faculty of Medicine, University of Los Andes, 750000 Santiago, ChilePotent immunosuppressive and regenerative properties of mesenchymal stem cells (MSCs) position them as a novel therapy for autoimmune diseases. This research examines the therapeutic effect of MSCs administration at different disease stages in experimental autoimmune encephalomyelitis (EAE). Classical and atypical scores of EAE, associated with Th1 and Th17 response, respectively, and also Treg lymphocytes, were evaluated. MSCs administration at the onset (EAE+MSConset) induced an important amelioration of the clinical signs and less lasting effect at the peak of EAE (EAE+MSCpeak). No effect was observed when MSCs were applied after EAE stabilization (EAE+MSClate). Surprisingly, EAE atypical signs were detected in EAE+MSCpeak and EAE+MSClate mice. However, no correlation was found in Th17/Th1 ratio. Interestingly, regardless of time administration, MSCs significantly reduced IL-6 and also T-bet, RORγT, and Foxp3 mRNA levels in brain samples of EAE mice. The downregulation of IL-6 could restore the well-functioning of the blood-brain barrier of EAE mice, correlated with a decreased number of brain infiltrating leukocytes. These results suggest that the inflammatory status is important to be considered for administering MSCs in autoimmune pathologies, leading to a further research to clarify the effect of MSCs for multiple sclerosis.http://dx.doi.org/10.1155/2015/140170 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mónica Kurte Javiera Bravo-Alegría Alexander Torres Vania Carrasco Cristina Ibáñez Ana María Vega-Letter Catalina Fernández-O’Ryan Carlos E. Irarrázabal Fernando E. Figueroa Rodrigo A. Fuentealba Claudia Riedel Flavio Carrión |
spellingShingle |
Mónica Kurte Javiera Bravo-Alegría Alexander Torres Vania Carrasco Cristina Ibáñez Ana María Vega-Letter Catalina Fernández-O’Ryan Carlos E. Irarrázabal Fernando E. Figueroa Rodrigo A. Fuentealba Claudia Riedel Flavio Carrión Intravenous Administration of Bone Marrow-Derived Mesenchymal Stem Cells Induces a Switch from Classical to Atypical Symptoms in Experimental Autoimmune Encephalomyelitis Stem Cells International |
author_facet |
Mónica Kurte Javiera Bravo-Alegría Alexander Torres Vania Carrasco Cristina Ibáñez Ana María Vega-Letter Catalina Fernández-O’Ryan Carlos E. Irarrázabal Fernando E. Figueroa Rodrigo A. Fuentealba Claudia Riedel Flavio Carrión |
author_sort |
Mónica Kurte |
title |
Intravenous Administration of Bone Marrow-Derived Mesenchymal Stem Cells Induces a Switch from Classical to Atypical Symptoms in Experimental Autoimmune Encephalomyelitis |
title_short |
Intravenous Administration of Bone Marrow-Derived Mesenchymal Stem Cells Induces a Switch from Classical to Atypical Symptoms in Experimental Autoimmune Encephalomyelitis |
title_full |
Intravenous Administration of Bone Marrow-Derived Mesenchymal Stem Cells Induces a Switch from Classical to Atypical Symptoms in Experimental Autoimmune Encephalomyelitis |
title_fullStr |
Intravenous Administration of Bone Marrow-Derived Mesenchymal Stem Cells Induces a Switch from Classical to Atypical Symptoms in Experimental Autoimmune Encephalomyelitis |
title_full_unstemmed |
Intravenous Administration of Bone Marrow-Derived Mesenchymal Stem Cells Induces a Switch from Classical to Atypical Symptoms in Experimental Autoimmune Encephalomyelitis |
title_sort |
intravenous administration of bone marrow-derived mesenchymal stem cells induces a switch from classical to atypical symptoms in experimental autoimmune encephalomyelitis |
publisher |
Hindawi Limited |
series |
Stem Cells International |
issn |
1687-966X 1687-9678 |
publishDate |
2015-01-01 |
description |
Potent immunosuppressive and regenerative properties of mesenchymal stem cells (MSCs) position them as a novel therapy for autoimmune diseases. This research examines the therapeutic effect of MSCs administration at different disease stages in experimental autoimmune encephalomyelitis (EAE). Classical and atypical scores of EAE, associated with Th1 and Th17 response, respectively, and also Treg lymphocytes, were evaluated. MSCs administration at the onset (EAE+MSConset) induced an important amelioration of the clinical signs and less lasting effect at the peak of EAE (EAE+MSCpeak). No effect was observed when MSCs were applied after EAE stabilization (EAE+MSClate). Surprisingly, EAE atypical signs were detected in EAE+MSCpeak and EAE+MSClate mice. However, no correlation was found in Th17/Th1 ratio. Interestingly, regardless of time administration, MSCs significantly reduced IL-6 and also T-bet, RORγT, and Foxp3 mRNA levels in brain samples of EAE mice. The downregulation of IL-6 could restore the well-functioning of the blood-brain barrier of EAE mice, correlated with a decreased number of brain infiltrating leukocytes. These results suggest that the inflammatory status is important to be considered for administering MSCs in autoimmune pathologies, leading to a further research to clarify the effect of MSCs for multiple sclerosis. |
url |
http://dx.doi.org/10.1155/2015/140170 |
work_keys_str_mv |
AT monicakurte intravenousadministrationofbonemarrowderivedmesenchymalstemcellsinducesaswitchfromclassicaltoatypicalsymptomsinexperimentalautoimmuneencephalomyelitis AT javierabravoalegria intravenousadministrationofbonemarrowderivedmesenchymalstemcellsinducesaswitchfromclassicaltoatypicalsymptomsinexperimentalautoimmuneencephalomyelitis AT alexandertorres intravenousadministrationofbonemarrowderivedmesenchymalstemcellsinducesaswitchfromclassicaltoatypicalsymptomsinexperimentalautoimmuneencephalomyelitis AT vaniacarrasco intravenousadministrationofbonemarrowderivedmesenchymalstemcellsinducesaswitchfromclassicaltoatypicalsymptomsinexperimentalautoimmuneencephalomyelitis AT cristinaibanez intravenousadministrationofbonemarrowderivedmesenchymalstemcellsinducesaswitchfromclassicaltoatypicalsymptomsinexperimentalautoimmuneencephalomyelitis AT anamariavegaletter intravenousadministrationofbonemarrowderivedmesenchymalstemcellsinducesaswitchfromclassicaltoatypicalsymptomsinexperimentalautoimmuneencephalomyelitis AT catalinafernandezoryan intravenousadministrationofbonemarrowderivedmesenchymalstemcellsinducesaswitchfromclassicaltoatypicalsymptomsinexperimentalautoimmuneencephalomyelitis AT carloseirarrazabal intravenousadministrationofbonemarrowderivedmesenchymalstemcellsinducesaswitchfromclassicaltoatypicalsymptomsinexperimentalautoimmuneencephalomyelitis AT fernandoefigueroa intravenousadministrationofbonemarrowderivedmesenchymalstemcellsinducesaswitchfromclassicaltoatypicalsymptomsinexperimentalautoimmuneencephalomyelitis AT rodrigoafuentealba intravenousadministrationofbonemarrowderivedmesenchymalstemcellsinducesaswitchfromclassicaltoatypicalsymptomsinexperimentalautoimmuneencephalomyelitis AT claudiariedel intravenousadministrationofbonemarrowderivedmesenchymalstemcellsinducesaswitchfromclassicaltoatypicalsymptomsinexperimentalautoimmuneencephalomyelitis AT flaviocarrion intravenousadministrationofbonemarrowderivedmesenchymalstemcellsinducesaswitchfromclassicaltoatypicalsymptomsinexperimentalautoimmuneencephalomyelitis |
_version_ |
1725661846903455744 |